Previous studies have reported that IL16 induces TME cells migration, which improves cancer therapeutic efficacy.[29] An increase in TNFSF13B‐TNFRSF13B could induce the proliferation of malignant cells in multiple myeloma.[30] Moreover, transcriptional regulation analysis showed that JUND transcription factors were significantly enriched and up‐regulated in resistant cells (Figure S2E,F, Supporting Information). Here, IL16 is linked to plasma cell myeloma.